Skip to content

The Age of Biology Has Begun.

AI is turning biology into an engineering discipline. Humain Ventures backs founders building the future of therapeutics, prevention, and human health.

Early partner · Deep technical underwriting · High-conviction support

What we believe

Building the Future of Human Health

Three convictions drive where we invest and how we partner with founders.

  • Tech Bio

    Biology Is Becoming an Engineering Discipline

    Computation, AI, and programmable biology are converging to change how drugs are built and disease is treated. Teams that treat biology as a design space will define the next era of therapeutics. This is not Biotech. It is Tech Bio.

    • AI-native therapeutics
    • Core Tech Bio infrastructure
  • The Lifespan Project

    Fixing the Incentives

    Outcomes follow incentives. The healthcare system rewards treatment over prevention. Founders who re-architect these incentives can reshape entire markets — and extend human healthspan.

    • Prevention-first health systems
    • Lifelong health accounts
  • Consumer Health

    Consumers Should Choose

    Wearables and longitudinal data turn health from episodic care into a continuous product surface. When consumers own their data and can act on it, they become the most powerful force in healthcare.

    • Wearables & continuous biosensing
    • Consumer-owned health data
  • “Biology is ready for its ChatGPT moment.”

    Eric SchmidtFormer CEO, Google
  • “The most important application of AI is biology.”

    Jensen HuangCEO, NVIDIA
  • “The greatest innovations of the next decade will be at the intersection of AI and biology.”

    Steve JobsCo-Founder, Apple

Portfolio

Companies Building the Future of Health

See portfolio
  • Unnatural Products

    AI-designed macrocyclic peptide therapeutics

    • Leading macrocyclic peptide platform
    • $3.5B+ in pharma partnerships since investment
    • Orally available 'Goldilocks' drugs

    AI + chemistry unlocking undruggable targets.

    Why we're excited about Unnatural Products
  • Cognitive Scientific

    Next-generation AI systems

    • 100–1000× efficiency gains
    • Lower energy, less data, faster iteration

    Foundational intelligence layer for Tech Bio.

    Why we're excited about Cognitive Scientific
  • Radicle Science

    Evidence infrastructure for consumer wellness

    • Rapid, digital clinical trials
    • Proof-as-a-service for the $480B supplement industry

    Clinical-grade validation for consumer health.

    Why we're excited about Radicle Science
  • NextSense

    Neural wearables for sleep and brain health

    • EEG-enabled sleep earbuds
    • Real-time brainwave monitoring
    • Deep sleep optimization

    Continuous brain measurement as a health platform.

    Why we're excited about NextSense
  • Profile Health

    A clinical operating system for personalized medicine

    • Genome, records and clinical data synthesized in one review
    • Patient review cut from four hours to under ten minutes

    AI that frees physicians to practice, not replaces them.

    Why we're excited about Profile Health
  • Impulse Labs

    Autonomous machine learning from a plain-English prompt

    • Production models without a data-science team
    • No-code dashboard, MCP server and REST API

    Proprietary models for teams that own the data.

    Why we're excited about Impulse Labs
  • Trace Health

    Passive biomarker tracking, beginning with urine

    • Toilet-mounted electrochemical biosensor
    • No test strips, no compliance burden

    Continuous chemistry instead of annual snapshots.

    Why we're excited about Trace Health
  • Chroma

    The open-source retrieval database for AI

    • 15M+ monthly downloads, built into LangChain and LlamaIndex
    • Chroma Cloud and the Context-1 search-agent model

    The context layer for AI agents.

    Why we're excited about Chroma
  • Devoted Health

    An integrated health plan and care organization for Medicare

    • Medicare Advantage plans with its own care delivery
    • Expanding to 34 states and 1,341 counties

    Health insurance rebuilt around the member, not the claim.

    Why we're excited about Devoted Health
  • Reactosome

    Synthetic cells for a new class of nucleic acid therapies

    • Gives cells an extra, synthetic nucleus
    • Reaches 10× more genes than traditional methods

    Gene therapy that goes beyond delivering a single gene.

    Why we're excited about Reactosome

See the whole portfolio

Investment ThesisA main thesis of Humain's investment strategy

The Lifespan Project

Reimagining healthcare incentives

Co-founded by Aneil Mallavarapu and Linea Avey, The Lifespan Project explores a prevention-first healthcare architecture that aligns incentives across consumers, insurers, and innovators.

Profile Health is the lead example.

  • Lifelong health accounts
  • Prevention-aligned economics
  • Consumer-owned health data
  • AI-guided health management

A new financial architecture for human longevity.

For Founders

Why Founders Work With Us

A different kind of early partner.

  • Deep technical underwriting
  • Platform-level thinking (not single-asset bets)
  • Engineering-first product intuition
  • Prevention-oriented worldview
  • Small, focused, high-conviction portfolio
  • Hands-on support at company formation stage

What we can help with

  • Technical diligence + roadmap
  • Research & clinical strategy
  • Partnerships & hiring

Leadership

Experienced Builders of Category-Defining Companies

  • Linea Avey

    Linea Avey

    • Co-Founder, 23andMe
    • Board of Fellows, Stanford School of Medicine
    • Founding Board, Rock Health
    • Director, Human Immunome Project
    • Advisor, Verily Life Sciences

    Built category-defining consumer health platforms.

  • Aneil Mallavarapu, PhD

    Aneil Mallavarapu, PhD

    • Mathematical biologist; award-winning scientist
    • Serial entrepreneur (5× founder)
    • AI, systems biology, drug engineering

    Applies computation to biological complexity.

  • Michael Staton

    Michael Staton

    • GP at Learn Capital for 8 years; grew AUM from ~$40M to ~$1.2B
    • Cofounder & GP, LearnStart, Learn Capital's seed fund
    • $400M+ LP capital raised; 220+ portfolio companies across platforms
    • 12 unicorns from ~90 early-stage conviction investments
    • 4 IPOs: Coursera, Udemy, Nerdy, Chime

    Fund formation, portfolio and LP stewardship.